Ephrem Awulachewz, Kuma Diriba, Asrat Anja, Firehiwot Belayneh
Background: Currently, coronavirus disease (COVID-19) was reported in more than 204 countries. As of April 10,2020, a total of 1,605,729 confirmed cases and 95,766 deaths had been reported worldwide. There are no approvedspecific antiviral agents targeting the novel virus. Convalescent plasma transfusion might be effective against theinfection. Food and drug administration (FDA) has also approved the emergency use of investigational COVID-19convalescent plasma to treat severely ill COVID-19 patients.
Objective: The aim of this study was to systematicallyreview disease outcome and effectiveness of convalescent plasma to treat COVID-19.
Method: We searched literaturepublished in English from December 20 /2019 to April 10/2020 on electronic databases. Using R software we haveconducted a systematic analysis, frequency, mean, standard deviation, and chi-square test.
Result: The average age ofthe participants in the included was 55.7 with a standard deviation of 13.9. The average days of recovery or testnegative for the COVID-19 PCR test after convalescent plasma therapy were 9.6 days (95% CI 2-30 days). About43%(9/21) had a history of comorbidity. The average date of recovery of patients with co-existing chronic diseases infected byCOVID 19 after convalescent plasmatherapy was about 12days relatively prolonged than patients without the co-existing disease (7.6 days). No series adverse effects have been demonstrated in patients who havereceivedconvalescent plasma transfusion.
Published Date: 2021-02-26; Received Date: 2021-02-05